Not checkedNot checked for notices yet.
PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19
James Logue, Arup R. Chakraborty, Robert Johnson and 15 more
Communications Biology · 2022
doi:10.1038/s42003-022-03766-2 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Compound-testing in a murine model for COVID-19 show that the prophylactic or therapeutic application of Apilimod and other PIKfyve inhibitors, the former being considered for human Phase II trials, worsens disease outcome with higher lung viral load and mortality.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.